Fig. 5.

Progression-free survival by median adenosine-signaling gene-signature score (efficacy analysis set). Patients who did not die or have disease progression were censored at their last evaluable response assessment. Values ≥ the median were assigned to the high group; values < the median were assigned to the low group. CI confidence interval, PFS progression-free survival